AIM ImmunoTech (AIM) CEO Thomas K. Equels Buys 11,000 Shares

What Happened Thomas K. Equels, CEO, President and a director of AIM ImmunoTech (AIM), reported a purchase of 11,000 common shares on 2026-09-16. The Form 4 lists the transaction as a Purchase (code P) at $0.21 per share for a total cost of $2,310. This was a buy (a cash outflow by the insider), which some investors view as a modest bullish signal, though the dollar amount is small.

Key Details

• Transaction date and price: 2026-09-16 — 11,000 shares at $0.21/sh, total $2,310.
• Transaction type: Purchase (Form 4 code P); described as "open market or private purchase" on the filing.
• Filing date: 2026-09-17 (filed the next day; appears to be timely).
• Shares owned after transaction: Not specified in the information provided.
• Footnotes/plans: No 10b5-1 plan, tax withholding, or other special footnotes noted in the provided excerpt.

Context Insider purchases can be informative, but this is a relatively small-dollar purchase ($2,310), so it may carry limited signal about insider conviction. The filing appears timely (filed one day after the transaction). As always, use insider activity as one input among many when evaluating a stock.